Endeavor BioMedicines Raises $132.5 Million in Oversubscribed Series C Financing Led by AyurMaya to Advance Pipeline of Transformational Medicines

Apr 24, 2024•over 1 year ago

Amount Raised

$133 Million

Round Type

series c

San Diego

Investors

T. Rowe Price AssociatesSilver Arch BioPiper Heartland Healthcare CapitalPerceptive AdvisorsOmega FundsLongitude CapitalEckuity CapitalAvidity PartnersAlly Bridge GroupAbrdn Inc.Woodline PartnersVelosity CapitalSym BiosisInvusFidelity Management & Research CompanyMatrix Capital ManagementAyur Maya

Description

Endeavor BioMedicines, Inc. has closed a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument. The oversubscribed round was led by AyurMaya, an affiliate of Matrix Capital Management, with participation from new investors including Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, and Woodline Partners; and strong support from existing investors.

Company Information

Company

Endeavor Biomedicines, Inc.

Location

12707 High Bluff Dr., Suite 300

San Diego, California, United States

About

Endeavor BioMedicines is a clinical stage company targeting the drivers of fibrosis and oncology. We combine best-in-class therapeutics with an evolving understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Our lead program, ENV-101, is a Hedgehog signaling inhibitor with demonstrated clinical activity that we are investigating in IPF. At Endeavor, we are an innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends